Novartis

Novartis
Basel, North West Switzerland
Web: Novartis external link
Lieu: Bâle
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Médecine 22.9
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model -   GIPAP was introduced 15 years ago and has provided approximately 75,000 patients access to free, cancer treatment -   The Max Foundation to lead program for patients and oversee supply chain ma
Médecine 20.9

Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surv

Médecine 14.9

51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under r

Médecine 12.9

Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that ou

Médecine 16.9

OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled -   Should a treatment pause be necessary, data showed almost 90% of

Médecine 13.9

Cosentyx (secukinumab) is the first and only fully human IL-17A   inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis -   Landmark data show that PASI 90 and PASI

Médecine 11.9

Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relaps




 
 
Logo Careerjet